Table 1.

Association of TRG with different clinicopathologic factors

Factor	TRG0 (n=67)	TRG1 (n=78)	TRG2 (n=78)	TRG3 (n=46)	Total (n=269)	P
Gender						0.066
Male	43	49	62	35	189
Female	24	29	16	11	80
Age (years)						0.387
<60	50	58	51	36	195
>60	17	20	27	10	74
Tumor location (cm)						0.456
<5	45	42	49	26	162
5-10	22	34	28	18	102
>10	0	2	1	2	5
Differentiation						0.273
Well-differentiated	2	3	4	2	11
Moderately-differentiated	53	61	67	42	223
Poorly-differentiated	12	14	7	2	35
Histologic typing						0.089
Adenocarcinoma	50	67	71	41	229
Mucinous adenocarcinoma	13	7	6	5	31
Signet ring cell carcinoma	4	4	1	0	9
Chemotherapy regimens						0.694
Single-capecitabine/5-FU	5	5	9	4	23
XELOX/FOLFOX	62	73	69	42	246
Pre-NACRT CEA (ng/mL)						0.503
<5*10-6	30	34	39	26	129
>5*10-6	37	44	39	20	140
Post-NACRT CEA (ng/mL)						0.002
<5*10-6	62	73	66	33	234
>5*10-6	5	5	12	13	35
Clinical T stage						0.022
T2	2	0	0	0	2
T3	25	39	25	12	101
T4	40	39	53	34	166
Clinical N stage						0.449
N0	31	36	33	15	115
N+	36	42	45	31	154
Pathologic T stage						<0.001
T0	61	0	0	0	61
T1	0	3	0	0	3
T2	2	23	13	8	46
T3	4	36	50	30	120
T4	0	16	15	8	39
Pathologic N stage						0.003
N0	56	51	42	24	173
N1	5	16	25	16	62
N2	6	11	11	6	34

Abbreviation: TRG, Tumor regression grade; NACRT, Neoadjuvant chemoradiotherapy; CEA, Carcinoembryonic antigen.